Weekly Healthcare Industry Financing Report (20240902): Innovations in Organ-on-a-Chip, Minimally Invasive Devices Attract Investment

【Organ Chip】Hepo Biotech was founded in December 2022, focusing on the innovative research and development of 3D organ models and organ-on-a-chip technologies, aiming to provide more reliable safety and efficacy evaluations for non-clinical drug research. Currently, Hepo Biotech has developed a range of mature products, including various 3D in vitro models such as liver, intestine, blood-brain barrier, nerve, and tumor models, which have been successfully applied in non-clinical drug research. The company has already established partnerships with Merck, Eli Lilly, Gilead, and Hengrui.

【Investor】Zhangke Seed Fund, Qingdao Zhenze Fund

【Nucleic Acid Drug R&D Services】Leaderna Therapeutics Ltd. was established on July 13, 2022, as a medical research and experimental development service provider focused on the development of nucleic acid drug projects and related technical research. Leaderna has built technology platforms for chemically modified and conjugated oligonucleotide drugs, extrahepatic chemical delivery, and hepatocyte delivery, concentrating on major chronic diseases. Through independent innovation and collaboration, the company has developed multiple R&D pipelines covering metabolic cardiovascular diseases such as abnormal blood pressure, blood lipids, and blood glucose, as well as central nervous system disorders. The Lipisense project for treating severe hypertriglyceridemia has entered phase I clinical trials, while the project for long-acting hypertension treatment is about to enter the clinical stage.

【Investor】HuaiGe Capital, DeHou Capital, ZhongKe ChuangXing

【EEG Detection】Neurogin is a high-tech enterprise that integrates the research, development, and production of medical devices, rooted in the fields of life sciences, clinical medicine, and artificial intelligence. With profound expertise in brain science, neuroscience, biosignal processing, and artificial intelligence, the company is committed to applying cutting-edge interdisciplinary technologies to brain science research and clinical diagnostics. It provides advanced research equipment to biological and medical research institutions and offers reliable monitoring and auxiliary diagnostic tools to clinical and health management organizations.

【Investor】Pinehurst Capital

【Host-Free Ultrasonic Scalpel】Ansukang Medical is an innovative pharmaceutical equipment developer, with its flagship product being the next-generation cordless ultrasonic scalpel. Compared to traditional products, it is more compact and eliminates the need for a main unit, achieving miniaturization and intelligence. The company is committed to providing Chinese medical professionals with surgical instruments that offer superior performance and are easier to use, manage, and maintain. The founding team members come from top multinational corporations and private enterprises, possessing extensive experience in product development, production, mass production quality control, and sales.

【Investor】Taiping Innovation, Legend Capital

【Endoscope】Langxin Medical Technology (Wuxi) Co., Ltd. was founded in 2022, with its registered office located in Wuxi, Jiangsu. It is an innovative medical device company focused on the prevention and treatment of digestive and metabolic diseases. The company's core team has deep technical expertise in fields such as optics, electronics, structure, software, algorithms, and processes. In the past, the core team successfully developed medical devices from scratch, including ECG machines, radiofrequency/microwave ablation equipment, and CT scanners. Within less than 20 months of starting operations, the company has submitted five product registrations, two of which have already received product registration certificates. These products are the world’s first transoral cholangioscope with special light functionality and its corresponding electronic endoscopic image processor. Additionally, the company has six other products in the trial production phase, which will soon be submitted for registration inspection. By May 2025, the company is expected to obtain 12 product registration certificates.

【Investor】Jinyu Maowu, Yangyun Capital

【Laser Minimally Invasive Equipment】Mil Medical Technology (Shenzhen) Co., Ltd. is committed to becoming a world-class innovative enterprise in laser minimally invasive medical technology. The team consists of multiple Tsinghua University Ph.D.s, top experts in medical-engineering interdisciplinary fields, experienced software and hardware engineers, and seasoned marketing professionals. The company strategically focuses on the "laser + medical" field, emphasizing the provision of minimally invasive laser medical surgical equipment for vascular and proliferative tissue treatments, complementary auxiliary products, and system-level solution services for laser minimally invasive medical technologies tailored to medical companies. The company’s main businesses include the development, production, and sales of three categories of dental laser treatment devices and medical aesthetic laser treatment devices; customized development and production of urology laser treatment devices; and consulting services for medical lasers and supporting solutions.

【Investor】Infinity Capital

【Immune Diagnosis】Shenzhen Jinzhun Bio-Medical Engineering Co., Ltd. is a national and Shenzhen dual high-tech enterprise dedicated to the research, development, production, sales, and service of in vitro diagnostic (IVD) reagents and instruments. The company owns the world's first quantum dot quantitative immunochromatographic platform, quantum dot fluorescent slide platform, and lyophilized powder quality control product platform, with product categories covering inflammation, cardiovascular diseases, kidney injury, and other fields. With the goal of setting the gold standard in the industry, Jinzhun places high importance on product quality. It pioneered the concepts of "full-process quality control" and "equipment standardization" in the industry and has obtained CE certification.

【Investor】Undisclosed

【AI+Traditional Chinese Medicine Health Management】JueCore Biotech is a high-tech enterprise established in 2022, focusing on providing AI health analysis and precision nutrition health management solutions based on Traditional Chinese Medicine (TCM) theory by utilizing artificial intelligence technology. The company can integrate Lingyun Optics' intelligent vision imaging solutions with Zhipu AI's multimodal large models to promote the modernization of traditional Chinese medicine, offering users more accurate and personalized health management services.

【Investors】Zhipu

【Krill Oil】Founded in 2018, Fengshi Technology is an innovative marine science enterprise with the strategic direction of "marine science, medical nutrition." Since its establishment, it has achieved an annual compound growth rate of 395% in sales, with a product repurchase rate of 40%. Its krill oil market share ranks first globally in online sales. The company has established six global research and development centers in China, Germany, New Zealand, and other countries, focusing on cutting-edge R&D technologies for Antarctic krill. It has led multiple scientific research projects and high-end conferences in the krill oil industry, participated in formulating three national standards and eight group standards, and obtained 31 intellectual property rights, including nine invention patents.

【Investor】ADATA Technology, Cathay Fund

[Synthetic Biology]MicroSynth BioTech, established in 2021, is a biomanufacturing company based on synthetic biology technology. It is committed to producing various compounds in a low-carbon, energy-saving, and sustainable manner for application in pharmaceuticals, daily chemicals, agriculture, food, feed, and materials. Through the complete biosynthesis pathways of active natural products, it replaces inefficient production methods such as traditional planting extraction and animal tissue extraction, reducing the occupation of arable land resources and the hunting of rare animals. By designing, directing the evolution, and optimizing the expression of key enzymes, it revolutionizes the organic synthesis technology route of active pharmaceutical ingredients (APIs), lowering API production costs while avoiding environmental pollution caused by chemical synthesis processes. Drawing inspiration from deep-sea organisms, it seeks valuable bioactive molecules for application in daily chemical products like whitening, moisturizing, sun protection, and oxygen free radical repair. By designing and modifying microorganisms to secrete various plant growth promoters, it applies these to agricultural production to increase the yield of grain crops and improve the color and taste of cash crops, providing an alternative technical route to genetically edited crops for food security.

【Investors】Zhonggu Group Shunxi Fund, Henan Investment Group, Shenzhen Capital Group